Verastem Trumpets Early Clinical Results For FAK Program, Discloses Timelines And Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
Addressing an audience of 150 attendees at its first clinical-stage R&D day on July 11, Verastem Inc. put forward its new senior executive team, as well as an eminent authority in cancer stem cell biology, to describe its clinical progress thus far, and its future plans.